Page 444 - Best Practice Oral Presentation SP Sharing2025

I28

ผลการศึกษา

Both groups demonstrated significant hemoglobin improvement after six months. The
treatment group attained a mean hemoglobin level of 10.06 ± 1.37 g/dL (P < 0.001), while the

control group reached 9.88 ± 1.73 g/dL (P = 0.001), though the intergroup difference was not

statistically significant. The treatment group exhibited significantly lower serum ferritin (447.66
± 175.36 ng/mL vs. 876.45 ± 617.48 ng/mL, P < 0.001), transferrin saturation (34.32 ± 11.65%

vs. 33.28 ± 14.15%, P = 0.039), and iPTH levels (220.17 ± 163.42 pg/mL vs. 245.59 ± 275.24

pg/mL, P = 0.021) relative to controls. No adverse events were reported.

อภิปรายผล
In hemodialysis patients with anemia and hyperferritinemia, the administration of

Ascorbic acid during dialysis exerts antioxidant effects, while tranexamic acid, an antifibrinolytic

agent that enhances platelet function, helps mitigate blood loss during dialysis. Moreover, the
combined administration of ascorbic acid and tranexamic acid significantly reduces

inflammatory markers, ferritin levels, transferrin saturation (TSAT), and intact parathyroid
hormone (iPTH) compared to ascorbic acid, with statistical significance.

สรุปและข้อเสนอแนะ
Intravenous ascorbic acid combined with tranexamic acid appears to be a safe and

effective intervention for improving hemoglobin levels while reducing ferritin, transferrin

saturation, and intact parathyroid hormone (iPTH) in hemodialysis patients. These findings
suggest that this therapeutic strategy may provide a viable approach for managing anemia of

hemodialysis. Extending the duration of the study and increasing the sample size may enhance

the reliability and validity of the research findings.